Sarepta appoints ex-Allergan President as new CEO

pharmafile | June 29, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sarepta Therapeutics 

Sarepta Therapeutics has announced the appointment of ex-Allergan President Doug Ingram as the company’s new CEO – it’s third in less than three years. He will replace Edward M Kaye, who will leave the company following an interim period during which he will serve in an advisory capacity to ensure a smooth transition.

Ingram brings with him over 20 years’ life sciences experience. Prior to his appointment as Allergan’s President, he had served the company as its President of Europe, Middle East and Africa, and has worked in a range of roles at the firm, including legal and regulatory affairs, pharmacovigilance and public relations. He has also served as President and CEO of Chase Pharmaceuticals, a neurodegenerative disorder-focused biotech which was eventually bought out by Allergan. He held the role for close to three years.     

“This is a transformational period in Sarepta Therapeutics’ evolution, and Doug is an exceptional executive with the vision, experience, and leadership skills required to realise the Company’s full potential during its next phase,” commented M Kathleen Behrens, Chair of Sarepta’s Board. “We look forward to officially introducing Doug during our second quarter earnings conference call. Our team remains steadfast in its goal to ensure patients with Duchenne muscular dystrophy (DMD) and their families have access to the best treatments. We look forward to working with Doug to continue helping those with serious unmet medical needs and thank Ed for his career-long pursuit to improve the lives of these patients, as well as his tremendous leadership to help bring Exondys 51 to patients and physicians.”

Ingram’s predecessor Dr Kaye also commented, remarking: “I am confident Sarepta has selected in Doug Ingram the right leader to build on our success to date and to drive value for the company as he has done for Allergan and Chase Pharmaceuticals. I am proud of our accomplishments over the past several years and more importantly I have enjoyed becoming a member of the Duchenne community. I look forward to supporting the company and Doug through this transition as we continue to advance our strong pipeline to full fruition.”

Sarepta is a US-based biopharmaceutical firm which focuses on the treatment of rare neuromuscular disorders through the development of unique RNA-targeted therapeutics. The company has seen a number of executives pass through its top role recently – current CEO Kaye took up the role in just April 2015 when he predecessor Christopher Garabedian resigned.

When quizzed on his appointment, Ingram himself noted: “I am excited to join Sarepta Therapeutics at such an important time in its history. Through the tireless work of Ed and his team, Sarepta has taken a leadership position in the treatment of Duchene muscular dystrophy, brought hope to children and their families suffering from this debilitating condition and proven an unmatched dedication to patient care. Sarepta has a mission that matters, a deep pipeline to support that mission, and employees and a board that are single-mindedly focused on success through improving the lives of those with devastating rare diseases. We will remain committed to the continued success of Exondys 51, and rapidly advancing our clinical pipeline and next-generation platform technology.”

Related Content

FDA pre-meeting report raises concerns over Sarepta’s gene therapy for Duchenne muscular dystrophy

The US Food and Drug Administration (FDA) has released a report in preparation for its …


Weekly Movers: XenoPort, Akari, Bayer…

Bayer-Monsanto story comes close on the heels of Sanofi-Medivation tussle as the pharma sector goes …


Shares at Sarepta Therapeutics jump after FDA delay in drug approval review

Sarepta Therapeutics (NASDAQ: SRPT) has witnessed a sharp rise in the price of its shares …

Latest content